Dovitinib (CAS: 915769-50-5)

Antineoplastic  medicine

Wei for is a kind of more effective oral small molecule targets more tyrosine kinase inhibitor, can directly effect on tumor cells and provide nutritional support for the tumor cells of blood vessels and matrix, which has inhibitory effect on a variety of growth factors, such as VEGFR1-3, FGFR1-3, PDGFRB, e – KIT, Ret, TraA and CSF – 1. Currently many wei for is in the third phase of clinical, clinical studies have shown that it for breast cancer, urinary tract carcinoma, prostate cancer and multiple myeloma, melanoma has obvious therapeutic effect. With the deepening of the clinical research, is expected to extend its scope of tumor treatment.

Wei for more, through the antiproliferative activity and antiangiogenesis survival showed antitumor activity. The drug is suitable for surgery/local treatment of patients with advanced HCC, requires a lesion larger than 1 cm in diameter, blood picture, liver function, good physical condition is good, did not receive any systemic treatment (surgery, radiotherapy, and allow 4 weeks outside intervention). Preparation: 5 – chloro – 2 – nitroaniline and N – methyl piperazine as raw material, after replacing, reduction, and beta ethoxy – beta – the amino propionic acid ethyl ester hydrochloride cyclization, finally to 2 – amino – 6 – fluorine benzene nitriles cyclization, for get more wei, the overall yield was 44.1%.